

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number  
**WO 03/087370 A1**

- (51) International Patent Classification<sup>7</sup>: **C12N 15/11**, 15/63, 15/10
- (21) International Application Number: PCT/FI03/00285
- (22) International Filing Date: 14 April 2003 (14.04.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
20020746 18 April 2002 (18.04.2002) FI
- (71) Applicant (*for all designated States except US*):  
**FINNZYMES OY** [FI/FI]; Riihitontuntie 14 B, FIN-02200  
ESPOO (FI).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **SAVILAHTI, Harri**  
[FI/FI]; Munkkiniemen puistotie 2 B 34, FIN-00330  
HELSINKI (FI). **TIEAHO, Ville** [FI/FI]; Koivutie 8,  
FIN-04480 HAARAJOKI (FI).
- (74) Agent: **OY JALO ANT-WUORINEN AB**; Iso  
Roobertinkatu 4-6 A, FIN-00120 HELSINKI (FI).
- (81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: METHOD AND MATERIALS FOR PRODUCING DELETION DERIVATIVES OF POLYPEPTIDES

(57) Abstract: The present invention describes an *in vitro* transposition-based methodology for generation of deletion derivatives of polypeptides. An artificial transposon containing at least partly within its transposon ends a modification with translation stop codons in three reading frames is provided. In the method, transposition complexes are assembled using the modified transposon and essentially random integrations into the target plasmid, containing a polypeptide coding nucleic acid of interest, are recovered as a plasmid pool. Subsequent manipulation steps including restriction enzyme digestions and ligation result in pools of mutant clones from which deletion derivatives of a polypeptide coding nucleic acid of interest and its respective deletion polypeptides could be produced.

**BEST AVAILABLE COPY**

WO 03/087370 A1

**Method and materials for producing deletion derivatives of polypeptides**

The present invention relates to genetic engineering and especially *in vitro* transposition. The invention describes a method and materials for producing deletion derivatives of polypeptide coding nucleic acids. In particular, the invention provides means for efficient generation of C-terminal deletions of polypeptides by the use of a modified transposon with translation stop codons in all three reading frames. The invention further provides a kit for producing said deletion derivatives.

**10 BACKGROUND OF THE INVENTION**

Thousands of different types of protein species constitute a major molecular component of cellular life. These molecules are composed of amino acid chains, the sequence of which is encoded by the genes in the organism's DNA. The protein function can be diverse and specific functions have been evolved for different cellular demands. Native wild type protein molecules can obviously be studied for their function biochemically and genetically. The data thus obtained can be informative but very often such information is relatively limited. A better description of protein function can be gained through mutational analysis in which various types of mutations are introduced into the protein primary sequence and the mutated proteins are then analyzed for their function. With current recombinant DNA technology (Sambrook et al. 1989, Sambrook and Russell 2001), generation of mutations is relatively easy and therefore mutational analysis of proteins has become a standard in functional studies of proteins.

In principle, three different types of mutations can be introduced into a protein sequence (i) substitutions, (ii) insertions, and (iii) deletions. In a substitution mutation, a particular amino acid (or an amino acid stretch) in a protein is changed to another (or to another amino acid stretch of same length). In an insertion, an amino acid or a stretch of amino acids is added to the protein thus increasing the length of the amino acid chain. In a deletion mutation, an amino acid or a stretch of amino acids are eliminated from the protein sequence and thus the protein becomes smaller in size.

Various mutagenesis methods are currently available for generation of different types of mutations. These methods are typically straightforward to use. However, in most of the cases the wanted mutations are generated one by one and, therefore, their construction is time-consuming and labor-intensive. It would be desirable if a number of mutations could be generated simultaneously. For certain types of insertion mutations this type of approach has been described (Hayes and Hallet 2000). However, an efficient method for simultaneous generation of substitution and deletion mutations is still lacking.

One of the *in vitro* transposition systems we utilised for the present invention was a bacteriophage Mu-derived transposition system that has recently been introduced (Haapa et al. 1999a) and shown to function efficiently in many types of molecular biology applications (Wei et al. 1997, Taira et al. 1999, Haapa et al 1999 ab, Vilen et al. 2001). Mu transposition proceeds within the context of protein-DNA complexes that are called DNA transposition complexes or transpososomes (Mizuuchi 1991, Savilahti et al. 1995). These complexes are assembled from a tetramer of MuA transposase protein and Mu-transposon-derived DNA-end-segments (i.e. transposon end sequences recognised by MuA) containing MuA binding sites. When the complexes are formed they can react in divalent metal ion-dependent manner with any target DNA and splice the Mu end segments into the target (Savilahti et al 1995). In the simplest case, the MuA transposase protein and a short 50 bp Mu right-end (R-end) fragment are the only macromolecular components required for transpososome assembly (Savilahti et al. 1995, Savilahti and Mizuuchi 1996). Analogously, when two R-end sequences are located as inverted terminal repeats in a longer DNA molecule, transposition complexes form by synapsing the transposon ends. Target DNA in Mu DNA transposition *in vitro* can be linear, open circular, or supercoiled (Haapa et al. 1999a).

Mu transposition complex, the machinery within which the chemical steps of transposition take place, is initially assembled from four molecules of MuA transposase protein that first bind specific binding sites in the transposon ends (Figs. 5A and 5B).

The 50 bp Mu right end DNA segment contains two of these binding sites (they are called R1 and R2 and each of them is 22 bp long, Savilahti et al. 1995). When two ends, each bound by two MuA monomers, meet, the transposition complex is formed through conformational changes, the nature of which are not fully understood because of a lack of atomic resolution structural data on Mu transpososomes. However, the assembly of

the minimal Mu transpososome is clearly dependent upon the correct binding of MuA transposase to Mu ends of the donor DNA. Thus, modifications in the conserved nucleotide sequence of transposon ends (e.g. R1 and R2 sequences in Mu R-end) should potentially have a negative effect on the efficiency of the transposition since every altered nucleotide conceivably interferes with the MuA binding. It has been documented (Lee and Harshey 2001, Coros and Chaconas 2001) that the two last base pairs in the Mu transposon end can be modified without severe effect on transpososome function. However, no detailed analysis has been conducted for elucidation of the effects of modified R1 and R2 binding sites. In one example (Laurent et al. 2000) a *NotI* restriction site was engineered close to the transposon end that changed one base pair in the R1 sequence. *In vivo* studies indicate that within the R1 and R2 sequences mutations generally have negative effects on transposition efficiency (Groenen et al. 1985, 1986). In addition, these effects are typically additive.

## SUMMARY OF THE INVENTION

In this invention we describe a general methodology for making deletion derivatives of polypeptides using *in vitro* DNA transposition system. The method of the invention can be used to generate a number of deletion-derivatives of polypeptide coding nucleic acids simultaneously and with ease.

We utilised modified transposons that allowed us to generate C-terminal deletion derivatives of polypeptides. The methodology should be applicable to any protein, the encoding nucleic acid sequence (e.g. a gene) of which is cloned in a plasmid or other DNA vector.

In one aspect, the invention features a transposon nucleic acid comprising a genetically engineered translation stop signal in three reading frames at least partly within a transposon end sequence, or preferably within transposon end binding sequence, recognised by a transposase.

In various embodiments the transposon nucleic acid of the invention may contain a selectable marker and/or reporter gene. In one preferable embodiment the transposon

end sequence of said transposon nucleic acid is Mu end sequence recognised by MuA transposase. In one particular embodiment said Mu end sequence is Mu R-end sequence.

- 5 In another preferred embodiment of the invention the modified transposon is a Tn7-derived transposon.

In a second aspect, the invention provides a method for producing a deletion derivative of a polypeptide coding nucleic acid comprising the steps of:

- 10 (a) performing a transposition reaction in the presence of the transposon nucleic acid of the invention and a target nucleic acid containing a polypeptide coding nucleic acid of interest, (b) recovering a target nucleic acid having said transposon nucleic acid incorporated in said polypeptide coding nucleic acid.

- 15 In a preferred embodiment the method of the invention further comprises a step of (c) expressing said polypeptide coding nucleic acid having said transposon nucleic acid incorporated.

- 20 In a third aspect, the invention provides a kit for producing deletion derivatives of polypeptide coding nucleic acids. The kit comprises the transposon nucleic acid of the invention.

In a fourth aspect, the invention features use of the transposon nucleic acid of the invention for producing deletion derivatives of polypeptide coding nucleic acids.

25

The term "transposon", as used herein, refers to a nucleic acid segment, which is recognised by a transposase or an integrase enzyme and which is essential component of a functional nucleic acid-protein complex capable of transposition (i.e. a transpososome).

30

The term "transposase" used herein refers to an enzyme, which is an essential component of a functional nucleic acid-protein complex capable of transposition and

which is mediating transposition. The term "transposase" also refers to integrases from retrotransposons or of retroviral origin.

The expression "transposition reaction" used herein refers to a reaction wherein a transposon inserts into a target nucleic acid. Essential components in a transposition reaction are a transposon and a transposase or an integrase enzyme or some other components needed to form a functional transposition complex. The method and materials of the present invention are exemplified by employing *in vitro* Mu transposition (Haapa et al. 1999ab and Savilahti et al. 1995) or transposition system of Tn7 (Craig, 1996). Other transposition systems can be used as well. Examples of such systems are Tyl (Devine and Boeke, 1994, and International Patent Application WO 95/23875), Tn 10 and IS 10 (Kleckner et al. 1996), Mariner transposase (Lampe et al., 1996), Tc1 (Vos et al., 1996, 10(6), 755-61), Tn5 (Park et al., 1992), P element (Kaufman and Rio, 1992) and Tn3 (Ichikawa and Ohtsubo, 1990), bacterial insertion sequences (Ohtsubo and Sekine, 1996), retroviruses (Varmus and Brown 1989) and retrotransposon of yeast (Boeke, 1989).

The term "transposon end sequence" used herein refers to the conserved nucleotide sequences at the distal ends of a transposon. The transposon end sequences are responsible for identifying the transposon for transposition.

The term "transposon end binding sequence" used herein refers to the conserved nucleotide sequences within the transposon end sequence whereto a transposase specifically binds when mediating transposition.

The term "target nucleic acid" used herein refers to a nucleic acid molecule containing a protein coding nucleic acid of interest.

The term "translation stop signal" used herein refers to the genetic code, which contains three codon triplets (UAA, UAG, UGA) for terminating the polypeptide chain production during protein synthesis in a ribosome. In a DNA strand the corresponding stop signal triplets are TAA, TAG and TGA.

The term "reading frame" used herein refers to any sequence of bases in DNA or RNA that codes for the synthesis of either a protein or a component polypeptide. The point of initiation of reading determines the frame, i.e. the way in which the bases will be grouped in triplets as required by the genetic code.

- 5 The term "genetic engineering" used herein refers to molecular manipulation involving the construction of artificial recombinant nucleic acid molecules.

The term "gene" used herein refers to genomic DNA or RNA that are translated into polypeptides.

10

## BRIEF DESCRIPTION OF THE DRAWINGS

### Figure 1.

- 15 Cat-Mu transposons: Cat-Mu containing wild type Mu ends, Cat-Mu(*NotI*) containing Mu ends with engineered *NotI* restriction site, which design is described in Laurent et al. 2000, and Cat-Mu(Stop x 3) containing Mu ends with engineered translation stop signal in three reading frames (SEQ ID NO:2). Transposon end sequences (i.e. inverted terminal repeats) are drawn as rectangles.

20

### Figure 2.

- Transposon end sequences of Cat-Mu transposons: Cat-Mu transposon containing wild type Mu ends (SEQ ID NO:3), Cat-Mu(*NotI*) containing Mu ends with engineered *NotI* restriction site described in Laurent et al. 2000 (SEQ ID NO:4), and Cat-Mu(Stop x 3) containing Mu ends with engineered translation stop signal in three reading frames (SEQ ID NO:1). Asteriks (\*) show modified nucleotides in the Mu ends of Cat-Mu(*NotI*) and Cat-Mu(Stop x 3).
- 25

### Figure 3.

- 30 Analysis of C-terminal deletion variants on DNA level. Plasmids bearing Cat-Mu(Stop x 3) transposon insertions (samples 1-24) were digested with BamHI, and they were analyzed on 1,8 % agarose gels. The length of the shortest fragment of each digest

corresponds roughly to the length of the deletion variant protein gene (0- ~650 bp). M = DNA standards.

**Figure 4.**

- 5 Analysis of C-terminal deletion variants on protein level. The sizes of the deletion variant proteins, as predicted by sequencing analysis, are marked below each lane as kilodaltons. M= molecular weight standard, C<sup>+</sup>= positive control, C<sup>-</sup>= negative control. Predicted deletion variant protein products are pointed out by arrows.

10 **Figures 5A and 5B**

5A, Mu transposition complex. 5B, the assembly of Mu transposition complex.

**Figure 6.**

- 15 Overall strategy for production of C-terminal deletion variants of genes encoding proteins.

**DETAILED DESCRIPTION OF THE INVENTION**

- It has been published previously that protein engineering applications will benefit from Mu-based transposon strategies since it was established that any DNA sandwiched between Mu ends could be utilised as artificial transposons (Haapa et al. 1999a). In, principle insertion mutations (e.g. by addition of epitope tags or protein domains) and deletion mutations (by addition of translation stop codons) were foreseen with this strategy. However, introduction of a translation stop codon between transposon ends would leave a number of encoded amino acid residues into the protein's C-terminus. Given that an effective Mu end is about 50 bp in length, minimally this strategy would leave approximately 18 extra amino acids attached in the protein C-terminus. Extra amino acids may interfere with the protein function, therefore it would be better to add the stop codons as close as possible to the transposon end. By modifying the nucleotides of the Mu R-end (total of 7 nucleotides were changed, 5 of said nucleotides reside in Mu R1 sequence), we managed to place three stop codons in three reading frames very close to the Mu R-end resulting in transposons that still surprisingly retained their ability to form transposition complexes that were competent for transposition chemistry,
- 20  
25  
30



i.e. they facilitated the integration of the transposon *in vitro* into a target plasmid. In essence, all the possible C-terminal deletion variants can be generated.

We designed an artificial Cat-Mu(Stop)-transposon (SEQ ID NO:2) conferring resistance to chloramphenicol and Tn7-Kan(Stop)-transposon (SEQ ID NO:7) conferring resistance to kanamycin. Both contained in their ends modified base pairs providing three stop codons in three reading frames (figs. 1 and 2). The gene mediating resistance to chloramphenicol is used as a selectable marker. The term "selectable marker" refers to a gene that, when carried by a transposon, alters the ability of a cell harboring the transposon to grow or survive in a given growth environment relative to a similar cell lacking the selectable marker. The transposon nucleic acid of the invention preferably contains a positive selectable marker. A positive selectable marker, such as an antibiotic resistance, encodes a product that enables the host to grow and survive in the presence of an agent, which otherwise would inhibit the growth of the organism or kill it. The transposon nucleic acid of the invention may also contain a reporter gene, which can be any gene encoding a product whose expression is detectable and/or quantifiable by immunological, chemical, biochemical, biological or mechanical assays. A reporter gene product may, for example, have one of the following attributes: fluorescence (e.g., green fluorescent protein), enzymatic activity (e.g., luciferase, *lacZ*/ $\beta$ -galactosidase), toxicity (e.g., ricin) or an ability to be specifically bound by a second molecule (e.g., biotin). The use of markers and reporter genes in prokaryotic and eukaryotic cells is well-known in the art. In a preferred embodiment the transposon nucleic acid of the invention may also contain genetically engineered restriction enzyme sites. For example, the selectable marker gene within the transposon of the invention may influence the protein expression when a construct obtained by the method of the invention is inserted into a protein expression plasmid. It is therefore desirable to engineer a pair of unique restriction sites to flank the selectable marker gene. The marker can then be removed easily by the use of these sites and thus the final expression construct would not contain the marker gene.

Hence, one embodiment of the invention provides a transposon nucleic acid comprising a genetically engineered translation stop signal in three reading frames at least partly within a transposon end sequence, or preferably within transposon end binding

sequence, recognised by a transposase (i.e. at least one conserved nucleotide of the end sequence has been modified, preferably two, three, four or more conserved nucleotides have been modified). Preferably, the transposon nucleic acid of the invention comprises Mu or Tn7 transposon sequence. More preferably the transposon nucleic acid of the invention comprises Mu R-end sequence, e.g., the sequence of SEQ ID NO:1 or SEQ ID NO:5 (Mu-R end sequence not including 5' overhang, which thus can vary). In a transposon end sequence of the transposon nucleic acid of the invention, translation stop signals of three reading frames are in 5'-to-3' direction, preferably in succession close to each other at a very end of a transposon, thus the three stop signals are as near as possible the flanking sequence after the transposon is incorporated into a target. Furthermore, the transposon end sequences, which participate in the assembly of the transpososome discussed above, can be different from each other or they can be in different nucleic acid molecules. Preferably, both transposon end sequences participating in the transpososome have similar sequences (i.e. they are located as inverted terminal repeats).

The transposon nucleic acid of the invention is exemplified here by transposons of Mu (Examples 1-3) or Tn7 (Example 4) system. However, a person skilled in the art understands that teachings of this invention can be utilised in other transposon systems as well.

Another embodiment of the invention is a method for producing a deletion derivative of a polypeptide coding nucleic acid comprising the steps of:

(a) performing a transposition reaction in the presence of a target nucleic acid containing a polypeptide coding nucleic acid (e.g. a gene) of interest and in the presence of a transposon containing a genetically engineered translation stop signal sequence in three reading frames at least partly within a transposon end sequence recognised by a transposase, (b) recovering a target nucleic acid having said transposon incorporated in said gene.

The transposition reaction (a) includes a transposon in a form of linear DNA molecule, transposase protein (e.g. MuA), and a target DNA as macromolecular components. Additionally, the transposition reaction contains suitable buffer components including

Mg<sup>2+</sup> ions critical for chemical catalysis. Buffer components such as glycerol and DMSO (or related chemicals or solvents) somewhat relax the requirements for transposition reaction (Savilahti et al. 1995). Transposon DNA, in principle, can be of any length given that it in each end contain a transposon (e.g. Mu or Tn7) end sequence.

5 Typically, target DNA is in a form of circular plasmid. However, any double-stranded DNA molecule more than 25 bp is expected to serve as efficient target molecule (Savilahti et al. 1995, Haapa-Paananen et al. 2002). In transposition reaction the reaction components are incubated together; during the incubation transposition complexes first form and then react with target DNA splicing the transposon DNA into  
10 target DNA. This process yields transposon integrations into target molecules. The stoichiometry of the reaction (excess target) generates target molecules each with a single integrated transposon. Most importantly, the integration site in each molecule can be different. Even though some sites in DNA are somewhat more preferred than others most of the phosphodiester bonds in DNA will be targeted (Haapa et al. 1999ab, Haapa-  
15 Paananen et al. 2002). In practice this means that the integration sites are selected essentially randomly.

In the Examples below deletion mutant libraries were planned to cover the gene of interest at least 10-fold, i.e. when the target gene was approximately 600 bp, the final  
20 pool should contain of a minimum of 6000 mutants. As a test protein we utilised 23 kDa yeast Mso1 protein (Aalto et al. 1997). Those skilled in the art can easily design different strategies for mutant library construction as such strategies are well-known in the art (see, e.g., Sambrook et al. 1989, Sambrook and Russell 2001).

25 A mutant library was produced as described in Example 2. Target nucleic acids with a transposon insertion were isolated by size-selective preparative agarose gel electrophoresis. A person skilled in the art may design different isolation methods as such methods are well-known in the art (see, for example, Current Protocols in Molecular Biology, eds. Ausubel et al, John Wiley & Sons: 1992). We screened  
30 individual deletion mutants by restriction analysis (fig. 3). This analysis demonstrates that in the library, there are variants of different sizes. A person skilled in the art can easily utilise different screening techniques. The screening step can be performed, e.g., by methods involving sequence analysis, nucleic acid hybridisation, primer extension or

antibody binding. These methods are well-known in the art (see, for example, Current Protocols in Molecular Biology, eds. Ausubel et al, John Wiley & Sons: 1992).

We sequenced 23 C-terminal mutants derived from Example 2. All the mutants carried  
5 the translation stop codons in three reading frames.

Finally, the protein expression analysis (fig. 4) demonstrated that different deletion variant proteins are produced. Probably due to lack of resolution in the utilised gel system, the supposedly expressed protein was not detectable when the deletion  
10 derivative was 8 kDa or smaller. Alternatively, very small versions of the Mso1 protein may be proteolytically degraded inside the cells.

A further embodiment of the invention is a kit providing means for producing deletion derivatives of protein coding nuclear acid sequences. The kit comprises the transposon  
15 nucleic acid of the invention. The kit can be packaged in a suitable container and preferably it contains instructions for using the kit.

The results of the invention show that, unexpectedly, it is possible to substantially modify conserved sequences of transposon ends without critically compromising the  
20 competence of the modified transposon to assemble transposition complexes and thereafter carry out transposition chemistry. Thus, the invention provides a straightforward solution to the problem of extra amino acids attached in the protein C-terminus of the deletion derivative which could be produced by a conventional transposition system, wherein the transposon used contains the translation stop signals  
25 between the transposon ends.

The present invention is further described in the following examples, which are not intended to limit the scope of the invention.

## EXAMPLES

## EXAMPLE 1

5 ***In vitro* transposition reaction**

*In vitro* transposition reaction (25 µl) contained 720 ng cat-Mu(Stop) transposon as a donor, 500 ng plasmid pHis6-MSO1 as a target nucleic acid, 0.2 µg MuA, 25 mM Tris-HCl at pH 8.0, 100 µg/ml BSA, 15% (w/v) glycerol, 0.05% (w/v) Triton X-100, 126 mM NaCl and 10 mM MgCl<sub>2</sub>. The reaction was carried out at 30°C for 4h.

10

Further details and variables of *in vitro* Mu transposition are described in Haapa et al. 1999ab and Savilahti et al. 1995, incorporated herein by reference.

## EXAMPLE 2

15

**Generation of a pool of mutants with C-terminal deletions in Mso1**

*In vitro* transposition reactions with Stop-Mu were performed essentially as described in Haapa et al. (1999a) with the exception that they contained 720 ng donor DNA (Stop-Mu x 3) and 0,88 µg MuA. Ten reactions were pooled, phenol and chlorophorm  
20 extracted, ethanol precipitated, and resuspended in 30 µl of water. Several 1 µl aliquots were electrotransformed, each into 25 µl of DH5α electrocompetent cells, as described (Haapa *et al.* 1999a). Transposon-containing plasmid clones were selected on LB plates containing Ap and Cm. A total of ~6×10<sup>5</sup> colonies were pooled and grown in selective LB-Ap-Cm medium at 37 °C for 3h after which plasmid DNA was prepared from the  
25 pool with Qiagen Plasmid Midi kit. This plasmid preparation was subjected to a *Xho*I-*Hind*III double digestion and preparative agarose gel electrophoresis. The DNA fragment corresponding to transposon insertions into the *Mso*I-containing DNA fragment was isolated with QIAquick Gel Extraction Kit (Qiagen). This fragment was then ligated into the plasmid pHis6-MSO1 vector *Xho*I-*Hind*III backbone to generate a  
30 construct pool with transposon insertions located only within the *Mso*I gene. After ligation, a pool of plasmids from ~5×10<sup>4</sup> colonies was prepared as described above. Approximately 110 000 colonies were pooled. Transposon-carrying *Mso*I fragments were cloned into clean vector backbone as described above and approximately 11 000

colonies were pooled in the final C-terminal deletion mutant library. At all stages, the transformants were selected with Ap and Cm.

### EXAMPLE 3

5

#### Restriction and expression analysis of deletion mutants

Mutant clones were analyzed for deletions by *Bam*HI digestion and DNA sequencing. For protein expression analysis, single mutant plasmids were introduced into BL21(DE3) expression strain. Selective medium was inoculated with o/n culture of bacteria containing mutant plasmid and grown until OD<sub>600</sub> was 0,4-0,7. Protein expression was induced with 1 mM IPTG for 3 hours and samples were withdrawn for SDS-PAGE analysis. Bacterial lysates were run on 15 % gels and stained with GelCode blue stain (Pierce) as recommended by the supplier.

### 15 EXAMPLE 4

#### Generation of deletion mutants with Tn7-Kan (Stop) transposon

*In vitro* Tn7 transposition reaction (20 µl) contained 40 ng Tn7-Kan (Stop) transposon (SEQ ID NO:7) as a donor, 100 ng plasmid pUC19 as a target nucleic acid, 7 ng TnsA protein, 10 ng TnsB protein, 20 ng TnsC\* protein, 25 mM Tris-HCl at pH 8.0, 50 µg/ml BSA, 2 mM DTT and 2 mM ATP. The reaction mixture was pre-incubated at 37°C for 10 min before addition of 30 mM magnesium acetate. After the addition the reaction was carried out at 37°C for 1 h.

25 The reaction mixture was precipitated with *n*-butanol to reduce the ionic strength and to concentrate DNA prior to electroporation (Thomas, 1994) and resuspended in 10 µl of water. 5 µl aliquot was electrotransformed into 50 µl of DH10B (Epicentre Technologies) electrocompetent cells. Transposon-containing plasmid clones were selected on LB plates containing kanamycin (20 µg/ml). Approximately 20000  
30 kanamycin resistant colonies were recovered per 1 µg target DNA. Three clones were picked from the transformation plates and grown in LB-Kn medium at 37°C overnight after which plasmid DNA was prepared from the cultures with QiaPrep Spin Miniprep Kit. The Tn7-Kan (Stop) transposon insertion sites were analyzed by DNA sequencing.

All the mutants carried the translation stop codons in six reading frames and in each case, the integrated transposon was flanked by a 5-bp target site duplication generated in TnsABC\*-mediated transposition.

## 5 MATERIALS AND METHODS

### **Bacteria, media, enzymes and reagents**

Bacterial cultures were grown in Luria broth supplemented with appropriate antibiotics: ampicillin (Ap) at 100 µg/ml, chloramphenicol (Cm) at 10 µg/ml and kanamycin (Kn)  
10 at 20 µg/ml when required. *Escherichia coli* strains were DH5α (Life Technologies), BL21(DE3) (Novagen), and DH10B (Epicentre Technologies). MuA protein was purified in collaboration with Finnzymes (Espoo, Finland) essentially as described (Baker *et al.* 1993, Haapa *et al.* 1999a). TnsA, TnsB and TnsC\* proteins were purchased from New England Biolabs. Restriction enzymes and T4 DNA ligase were  
15 from New England Biolabs and Promega, Triton X-100 from Roche. Standard DNA techniques were performed as described (Sambrook and Russell 2001). Enzymes were used as recommended by suppliers. Sequencing was carried out at the sequencing service unit of the Institute of Biotechnology, University of Helsinki.

### 20 **Plasmids and transposons**

Plasmid pHis6-MSO1 contains the 633 bp MsoI gene as an insert (Aalto *et al.* 1997). The Cat-Mu(Stop) transposon (1254 bp) is a derivative of the Cat-Mu transposon (Haapa *et al.* 1999a), and they encode resistance to chloramphenicol (fig. 1 and 2). The Cat-Mu(Stop)-transposon ends were engineered to carry translation stop signals for  
25 both 5'-to-3' directions of dsDNA in all three reading frames. The Tn7-Kan (Stop) transposon is a derivative of the pGPS1.1 transposon (New England Biolabs) and it encodes resistance to kanamycin. The Tn7-Kan (Stop) transposon ends were engineered to carry translation stop signals for both 5'-to-3' directions of dsDNA in all three reading frames. Tn7-Kan (Stop) transposon sequence is 4814 bp in length (SEQ ID NO:7) and  
30 nucleotides 3093-4791 set forth in SEQ ID NO:7 constitutes the transposable element. Modified nucleotides were at the positions of 3095, 3097, 3099, 3101, 3103, 4781, 4783, 4785, 4787, and 4789 set forth in SEQ ID NO:7.

Tn7-Kan (Stop) transposon was constructed from PCR-amplified fragments. The transposable fragment was amplified with primers 5' acg gtg agt gag tag aaa ata gtt ggg aac tgg ga 3' (SEQ ID NO:8) and 5' cgt atg agt gag tag aat aaa gtc tta aac tga aca aaa tag a 3' (SEQ ID NO:9) using the plasmid pGPS1.1 as template DNA (New England Biolabs) and the vector fragment was amplified with primers 5' aag tag ctt ttc tgt gac tgg t 3' (SEQ ID NO:10) and 5' gat ggc atg aca gta aga gct 3' (SEQ ID NO:11) using the plasmid pGPS1.1 (New England Biolabs) as template DNA.

Sequencing was performed using the primer 5'-gct agt tat tgc tca gcg g-3' (SEQ ID NO:5). Sequencing of Tn7-Kan (Stop) transposon insertion sites in pUC19 plasmid was carried out using Model 4200 DNA Sequencer (LI-COR). Sequencing was performed using IRD700-labeled primers 5' agc tgg cga aag ggg gat gtg 3' (SEQ ID NO:12) and 5' tta tgc ttc cgg ctc gta tgt tgt gt 3' (SEQ ID NO:13).



## REFERENCES

- 5     **Aalto, M. K., Jäntti, J., Östling, J., Keränen, S. & Ronne, H.** 1997. Mso1p: A yeast protein that functions in secretion and interacts physically and genetically with Sec1p. *Proc. Natl. Acad. Sci. USA* **94**: 7331-7336.
- Berg, D. E., and M. M. Howe (ed.).** 1989. *Mobile DNA*. American Society for Microbiology, Washington D. C.
- 10    **Boeke J. D.** 1989. Transposable elements in *Saccharomyces cerevisiae* in *Mobile DNA*.
- Chaconas, G., B. D. Lavoie, and M. A. Watson.** 1996. DNA transposition: jumping gene machine, some assembly required. *Curr. Biol.* **6**:817-820.
- 15    **Coros, C. J., and G. Chaconas.** 2001. Effect of mutations in the Mu-host junction region on transpososome assembly. *J. Mol. Biol.* **310**:299-309.
- Craig N. L.** 1996. Transposon Tn7. *Curr. Top. Microbiol. Immunol.* **204**: 27-48.
- 20    **Craigie, R., and K. Mizuuchi.** 1987. Transposition of Mu DNA: joining of Mu to target DNA can be uncoupled from cleavage at the ends of Mu. *Cell.* **51**:493-501.
- Devine, S.E. and Boeke, J.D.,** *Nucleic Acids Research*, 1994, **22**(18): 3765-3772.
- 25    **Groenen, M. A. M., and P. van den Putte.** 1986. Analysis of the ends of bacteriophage Mu using site-directed mutagenesis. *J. Mol. Biol.* **189**:597-602.
- 30    **Groenen, M. A. M., E. Timmers, and P. van den Putte.** 1985. DNA sequences at the ends of the genome of bacteriophage Mu essential for transposition. *Proc. Natl. Acad. Sci. USA.* **82**:2087-2091.

**Haapa, S., S. Taira, E. Heikkinen, and H. Savilahti.** 1999a. An efficient and accurate integration of mini-Mu transposons *in vitro*: a general methodology for functional genetic analysis and molecular biology applications. *Nucleic Acids Res.* **27**:2777-2784.

- 5 **Haapa, S., S. Suomalainen, S. Eerikäinen, M. Airaksinen, L. Paulin, and H. Savilahti.** 1999b. An efficient DNA sequencing strategy based on the bacteriophage Mu *in vitro* DNA transposition reaction. *Genome Res.* **9**:308-315.

- 10 **Haapa-Paananen, S., H. Rita, and H. Savilahti.** 2002. DNA transposition of bacteriophage Mu. A quantitative analysis of target site selection *in vitro*. *J. Biol. Chem.* **277**:2843-2851.

**Hayes, F., and B. Hallet.** 2000. Pentapeptide scanning mutagenesis: encouraging old proteins to execute unusual tricks. *Trends Microbiol.* **8**:571-577.

15

**Ichikawa H. and Ohtsubo E.,** *J. Biol. Chem.*, 1990, 265(31): 18829-32.

**Kahman, R., and D. Kamp.** 1979. Nucleotide sequences of the attachment sites of bacteriophage Mu. *Nature* **280**:247-250.

20

**Kaufman P. and Rio D.C.** 1992. *Cell*, 69(1): 27-39.

- Kleckner N., Chalmers R. M., Kwon D., Sakai J. and Bolland S.** TnIO and IS10 Transposition and chromosome rearrangements: mechanism and regulation *in vivo* and  
25 *in vitro*. *Curr. Top. Microbiol. Immunol.*, 1996, 204: 49-82.

**Lampe D.J., Churchill M.E.A. and Robertson H.M.,** *EMBO J.*, 1996, 15(19): 5470-5479.

- 30 **Laurent, L. C., M. N. Olsen, R. A. Crowley, H. Savilahti, and P. O. Brown.** 2000. Functional characterization of the human immunodeficiency virus type 1 genome by genetic footprinting. *J. Virol.* **74**:2760-2769.

Lee, I., and R. M. Harshey. 2001. Importance of the conserved CA dinucleotide at Mu termini. *J. Mol. Biol.* **314**:433-444.

Mizuuchi, K. 1992. Transpositional recombination: mechanistic insights from studies of Mu and other elements. *Annu. Rev. Biochem.* **61**:1011-1051.

Ohtsubo E. & Sekine Y. Bacterial insertion sequences. *Curr. Top. Microbiol. Immunol.*, 1996, 204:1-26.

Park B.T., Jeong M.H. and Kim B.H., *Taehan Misaengmul Hakhoechi*, 1992, 27(4): 381-9.

Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. *Molecular Cloning: a laboratory manual*, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y.

Sambrook, J. and D. W. Russell. 2001. *Molecular Cloning: a laboratory manual*, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y.

Savilahti, H. and K. Mizuuchi. 1996. Mu transpositional recombination: donor DNA cleavage and strand transfer in trans by the Mu transposase. *Cell* **85**:271-280.

Savilahti, H., P. A. Rice, and K. Mizuuchi. 1995. The phage Mu transpososome core: DNA requirements for assembly and function. *EMBO J.* **14**:4893-4903.

Sherratt, D. J. (ed.). 1995. *Mobile genetic elements*. Oxford University Press, Oxford, U.K.

Surette, M. G., S. J. Buch, and G. Chaconas. 1987. Transpososomes: stable protein-DNA complexes involved in the in vitro transposition of bacteriophage Mu DNA. *Cell* **49**: 253-262.

Taira, S., J. Tuimala, E. Roine, E. L. Nurmiaho-Lassila, H. Savilahti, and M. Romantschuk. 1999. Mutational analysis of the *Pseudomonas syringae* pv. *tomato* *hrpA* gene encoding Hrp pilus subunit. Mol. Microbiol. 34:737-744.

5 Thomas, M.R. 1994. Simple, effective cleanup of DNA ligation reactions prior to electro-transformation of *E. coli*. BioTechniques 16:988.

Varmus H and Brown. P. A. 1989. Retroviruses, in Mobile DNA. Berg D. E. and Howe M. eds. American society for microbiology, Washington D. C. pp.53-108.

10

Vilen, H., S. Eerikäinen, J. Tornberg, M. Airaksinen, and H. Savilahti. 2001. Construction of gene-targeting vectors: a rapid Mu in vitro DNA transposition-based strategy generating null, potentially hypomorphic, and conditional alleles. Transgenic Res. 10:69-80.

15

Vos J.C., Baere I. And Plasterk R.H.A., Genes Dev., 1996,10(6): 755-61.

Wei, S. Q., K. Mizuuchi, and R. Craigie. 1997. A large nucleoprotein assembly at the ends of the viral DNA mediates retroviral DNA integration. EMBO J. 16:7511-7520.

20

We claim:

1. A transposon nucleic acid comprising a genetically engineered translation stop signal in three reading frames at least partly within a transposon end sequence recognised by a transposase.  
5
2. The transposon nucleic acid according to claim 1, wherein said transposon contains a selectable marker and/or a reporter gene.
- 10 3. The transposon nucleic acid according to claim 1 or 2, wherein said transposon end sequence is Mu or Tn7 end sequence.
4. The transposon nucleic acid according to any one of claims 1-3, wherein said transposon end sequence is a transposon end binding sequence.  
15
5. The transposon nucleic acid according to claim 3, wherein Mu end sequence is Mu R-end binding sequence.
6. The transposon nucleic acid according to claim 5, wherein said transposon sequence is set forth in SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:5.  
20
7. The transposon nucleic acid according to claim 3, wherein said transposon sequence is set forth in SEQ ID NO:7.
- 25 8. The transposon nucleic acid according to any one of the preceding claim, wherein said transposon further contains a genetically engineered restriction enzyme site.
9. Method of producing a deletion derivative of a polypeptide coding nucleic acid comprising the steps of:  
30 (a) performing a transposition reaction in the presence of a target nucleic acid containing a polypeptide coding nucleic acid of interest and in the presence of a transposon containing a genetically engineered translation stop signal sequence in three reading frames at least partly within a transposon end sequence recognised by a

transposase, (b) recovering a target nucleic acid having said transposon incorporated in said protein coding nucleic acid.

10. The method according to claim 9 further comprising a step of (c) expressing said  
5 protein coding nucleic acid having said transposon incorporated.

11. The method according to claim 9 or 10, wherein said transposon comprises the transposon nucleic acid of any one of claims 2-8.

10 12. A kit for producing deletion derivatives of polypeptide coding nucleic acids comprising the transposon nucleic acid of any one of claims 1-8.

13. Use of the transposon nucleic acid of any one of claims 1-8 for producing deletion derivatives of polypeptide coding nucleic acids.

Figure 1.




Figure 2.







Figure 3.



4/7

Figure 4.





Figure 5A.

Mu DNA  
transposition  
complex



6/7





Figure 5B.

7/7

Figure 6.



## SEQUENCE LISTING

<110> Finnzymes Oy

<120> Method and materials for producing deletion derivatives  
of proteins

<130> STOP-MU

<140>

<141>

<160> 13

<170> PatentIn Ver. 2.1

<210> 1

<211> 54

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Modified Mu  
end sequence

<400> 1

gatctgattg attgaacgaa aaacgcgaaa gcgtttcacg ataaatgcga aaac 54

<210> 2

<211> 1254

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Modified Mu  
transposon

<400> 2

gatctgattg attgaacgaa aaacgcgaaa gcgtttcacg ataaatgcga aaacggatcc 60  
tatcgtcaat tattacctcc acggggagag cctgagcaaa ctggcctcag gcatttgaga 120  
agcacacggg cactactgctt ccggtagtca ataaaccggg aaaccagcaa tagacataag 180  
cggctattta acgaccctgc cctgaaccga cgaccgggtc gaatttgctt tcgaatttct 240  
gccattcatc cgcttattat cacttattca ggcgtagcaa ccaggcgctt aagggcacca 300  
ataactgcct taaaaaaatt acgccccgcc ctgccactca tcgcagtact gttgtaattc 360  
attaagcatt ctgccgacat ggaagccatc acaaacggca tgatgaacct gaatcgccag 420  
cggcatcagc accttgctgc cttgcgtata atatttgccc atggtgaaaa cgggggacga 480  
gaagttgtcc atattggcca cgtttaaatc aaaactggtg aaactcaccg agggattggc 540  
tgagacgaaa aacatattct caataaaccg tttagggaaa taggccaggt tttcacgta 600  
acacgccaca tcttgcgaa atagtgttag aaactgccgg aaatcgctcg ggtattcact 660  
ccagagcgat gaaaacgttt cagtttgctc atggaaaacg gtgtaacaag ggtgaacact 720  
atcccatatc accagctcac cgtctttcat tgccatacgt aattccggat gagcattcat 780  
caggcgggca agaattgtgaa taaaggccgg ataaaacttg tgcttatttt tctttacggt 840  
ctttaaaaag gccgtaatat ccagctgaac ggtctgggta taggtacatt gagcaactga 900  
ctgaaatgcc tcaaaatggt ctttacgatg ccattgggat atatcaacgg tggatatatc 960  
agtgtttttt ttctccattt tagcttcctt agctcctgaa aatctcgaca actcaaaaaa 1020  
tacgcccggg agtgatctta tttcattatg gtgaaagttg gaacctctta cgtgccgatc 1080  
aacgtctcat tttcgccaaa agttggccca gggcttcccg gtatcaacag ggacaccagg 1140  
atttatttat tctgcgaagt gatcttcctg cacaggattt tattcggtcg aaaaggatcc 1200  
gttttcgcat ttatcgtgaa acgctttcgc gtttttcggt caatcaatca gatc 1254

<210> 3

<211> 54

<212> DNA

<213> Bacteriophage Mu

<400> 3

gatctgaagc ggcgacgaa aaacgcgaaa gcgtttcacg ataaatgcga aaac 54

<210> 4

<211> 54

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Modified Mu  
end sequence

<400> 4

gatctgcggc cgcgacgaa aaacgcgaaa gcgtttcacg ataaatgcga aaac 54

<210> 5

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Modified Mu  
end sequence without 5' overhang

<400> 5

tgattgattg aacgaaaaac gcgaaagcgt ttcacgataa atgcgaaaac 50

<210> 6

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Sequencing  
primer

<400> 6

gctagttatt gctcagcgg 19

<210> 7

<211> 4814

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Modified Tn7  
transposon

<400> 7

ggtaccctgt gaatgcgcaa accaaccctt ggcagaacat atccatcgcg tccgccatct 60  
ccagcagccg cagcggcgcg atctcgggca gcgttggtgc ctggccacgg gtgcgcatga 120

tcgtgctcct	gtcggttgagg	accgcgctag	gctggcgggg	ttgccttact	ggttagcaga	180
atgaatcacc	gatacgcgag	cgaacgtgaa	gcgactgctg	ctgcaaaacg	tctgcgacct	240
gagcaacaac	atgaatggtc	ttcgggtttcc	gtgtttcgta	aagtctggaa	acgcggaagt	300
cagcgccctg	caccattatg	ttccggatct	atgtcgggtg	cggagaaaga	ggtaatgaaa	360
tggcagatcc	ctggcttggt	gtccacaacc	gttaaaccct	aaaagcttta	aaagccttat	420
atattctttt	ttttcttata	aaacttaaaa	ccttagaggc	tatttaagtt	gctgatttat	480
attaatttta	ttgttcaaac	atgagagctt	agtacgtgaa	acatgagagc	ttagtacgtt	540
agccatgaga	gcttagtacg	ttagccatga	gggttttagt	cgtaaacaat	gagagcttag	600
tacgttaaac	atgagagctt	agtacgtgaa	acatgagagc	ttagtacgta	ctatcaacag	660
gttgaactgc	tgatcttcgg	atctatgtcg	ggtgcggaga	aagaggtaat	gaaatggcag	720
atccctggct	tggtgtccac	aaccgttaaa	ccttaaaagc	tttaaaagcc	ttatatattc	780
ttttttttct	tataaaactt	aaaaccttag	aggctattta	agttgctgat	ttatattaat	840
tttattgttc	aaacatgaga	gcttagtacg	tgaacatga	gagcttagta	cgttagccat	900
gagagcttag	tacgttagcc	atgagggttt	agttcgtaa	acatgagagc	ttagtacgtt	960
aaacatgaga	gcttagtacg	tgaacatga	gagcttagta	cgtactatca	acagggttgaa	1020
ctgctgatct	tcggatctat	gtcgggtgcg	gagaaagagg	taatgaaatg	gcatccggat	1080
ctgcatcgca	ggatgctgct	ggctaccctg	tggaaacac	acatctgtat	taacgaagca	1140
ttattgaagc	atztatcagg	gttattgtct	catgagcgga	tacatatattg	aatgtattta	1200
gaaaaataaa	caaatagggg	ttccgcgcac	atttccccga	aaagtgccac	ctgacgtcta	1260
agaaaccatt	attatcatga	cattaaccta	taaaaatagg	cgtatcacga	ggccctttcg	1320
tcttcaagaa	ttctcatggt	tgacagctta	tcatcgataa	gctttaatgc	ggtagtttat	1380
cacagttaaa	ttgctaaccg	agtcaggcac	cgtgtatgaa	atctaacaat	gcgctcatcg	1440
tcatcctcgg	caccgtcacc	ctggatgctg	taggcatagg	cttggttatg	ccggtactgc	1500
cgggcctcct	gcgggatatc	gtccattccg	acagcatcgc	cagtcactat	ggcgtgctgc	1560
tagcgctata	tgcgttgatg	caatttctat	gcgcaccctg	tctcggagca	ctgtccgacc	1620
gctttggccg	ccgcccagtc	ctgctcgctt	cgtactttgg	agccactatc	gactacgcga	1680
tcatggcgac	cacacccgtc	ctgtggatcc	tctacgccgg	acgcatcgta	gccggcatca	1740
ccggcgccac	aggtgcggtt	gctggcgctc	atatcgccga	catcaccgat	ggggaagatc	1800
gggctcgcca	cttcgggctc	atgagcgctt	gtttcggcgt	gggtatgggtg	gcaggccccg	1860
tgcccggggg	actgttgggg	gccatctcct	tgcattgcac	attccttgcg	gcggcggtgc	1920
tcaacggcct	caacctacta	ctgggctgct	tctaatagca	ggagtcgcat	aaggagagagc	1980
gtcgaccgat	gcccttgaga	gccttcaacc	cagtcagctc	cttcgggtgg	gcgcggggca	2040
tgactatcgt	cgccgcactt	atgactgtct	tctttatcat	gcaactcgta	ggacaggtgc	2100
cggcagcgct	ctgggtcatt	ttcggcgagg	accgctttcg	ctggagcgcg	acgatgatcg	2160
gcctgtcgct	tgcggtatct	ggaatcttgc	acgccctcgc	tcaagccttc	gtcactgggtc	2220
ccgccacca	acgtttcggc	gagaagcagg	ccattatcgc	cggcatggcg	gccgacgcgc	2280
tgggctacgt	cttgctggcg	ttcgcgcagc	gaggctggat	ggccttcccc	attatgattc	2340
ttctcgcttc	cggcggcacg	gggatgcccg	cgttgacagg	catgctgtcc	aggcaggtag	2400
atgacgacca	tcagggacag	cttcaaggat	cgctcgcggc	tcttaccagc	ctaacttcga	2460
tcattggacc	gctgatcgtc	acggcgattt	atgccgcctc	ggcgagcaca	tggaacgggt	2520
tggcatggat	tgtaggcgcc	gccctatacc	ttgtctgcct	ccccgcgttg	cgtcgcgggtg	2580
catggagccg	ggccacctcg	acctgaatgg	aagccggcgg	cacctcgcta	acggattcac	2640
cactccaaga	attggagcca	atcaattctt	gcgggagaact	gtgaatgcgc	aaaccaaccc	2700
ttggcagaac	atatccatcg	cgtccgccat	ctccagcagc	cgcacgcggc	gcattctcggg	2760
cagcggtggg	tcttgggctg	gcattgaccc	tgagtgattt	ttctctgggtc	ccgccgcac	2820
cataccgcca	gttggtttacc	ctcacaacgt	tccagtaacc	gggcatgttc	atcatcagta	2880
accggtatcg	tgagcatcct	ctctcgtttc	atcgggtatca	ttacccccat	gaacagaaat	2940
cccccttaca	cggaggcatc	agtgaacaaa	caggaaaaaa	ccgcccttaa	catggccccg	3000
tttatcagaa	gccagacatt	aacgcttctg	gagaaactca	acgagctgga	cgcggatgaa	3060
caggcagagc	tcttactgtc	atgccatccg	tatgagttag	tagaataaag	tcttaaaactg	3120
aacaaaatag	atctaaacta	tgacaataaa	gtcttaaaact	agacagaata	gttgtaaact	3180
gaaatcagtc	cagttatgct	gtgaaaaagc	atactggact	tttgttatgg	ctaaagcaaaa	3240
ctcttcattt	tctgaagtgc	aaattgcccg	tctgattaaa	gaggggcgtg	gggtcgacgc	3300
ggccgctaac	tataacgggtc	ctaaggtagc	gagtttaaac	gatatcggtg	ccggccgcgcg	3360
ctgaggtctg	cctcgtgaag	aagggtgttc	tgactcatat	caggcctgaa	tcgccccatc	3420
atccagccag	aaagtgaagg	agccacgggt	gatgagagct	ttgttgtagg	tggaccagtt	3480
ggtgattttg	aacttttgct	ttgccacgga	acggtctgcg	ttgtcgggaa	gatgcgtgat	3540
ctgatccttc	aactcagcaa	gagttcgatt	tattcaacaa	agccgccgtc	ccgtcaagtc	3600
agcgtaaatg	tctgccagtg	ttacaaccaa	ttaaccaatt	ctgattagaa	aaactcatcg	3660
agcatcaaat	gaaactgcaa	tttattcata	tcaggattat	caataccata	tttttgaaaa	3720
agccgtttct	gtaatgaagg	agaaaaactca	ccgaggcagt	tccataggat	ggcaagatcc	3780



```

tggatcgggt ctgcgattcc gactcggtcca acatcaatac aacctattaa tttcccctcg 3840
tcaaaaataa ggttatcaag tgagaaatca ccatgagtga cgactgaatc cggtgagaat 3900
ggcaaaagct tatgcatttc tttccagact tgttcaacag gccagccatt acgctcgtca 3960
tcaaaatcac tcgcatcaac caaaccggtta ttcattcgtg attgcgcttg agcgagacga 4020
aatacgcgat cgctgtttaa aggacaatta caaacaggaa tcgaatgcaa ccggcgagg 4080
aacactgcca gcgcatcaac aatattttca cctgaatcag gatattcttc taataacctg 4140
aatgctgttt tcccggggat cgcagtggtg agtaaccatg catcatcagg agtacggata 4200
aaatgcttga tggtcggaag aggcataaat tccgtcagcc agtttagtct gaccatctca 4260
tctgtaacat cattggcaac gctacctttg ccatgtttca gaaacaactc tggcgcatcg 4320
ggcttcccat acaatcgata gattgtcgca cctgattgcc cgacattatc gcgagcccat 4380
ttatacccat ataaatcagc atccatgttg gaatttaatc gcggcctcga gcaagacgtt 4440
tcccgttgaa tatggctcat aacacccctt gtattactgt ttatgtaagc agacagtttt 4500
attgttcatt atgatatatt tttatcttgt gcaatgtaac atcagagatt ttgagacaca 4560
acgtggctta ctaggatccg atatcattta aatctaggga taacagggtg atactagtgt 4620
cgaccaacca gataagtga atctagttcc aaactatttt gtcattttta attttcgtat 4680
tagcttacga cgctacaccc agttcccatc tattttgtca ctcttcctta aataatcctt 4740
aaaaactcca tttccacccc tcccagttcc caactatttt ctactcactc accgtaagat 4800
gcttttctgt gact 4814

```

&lt;210&gt; 8

&lt;211&gt; 35

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:  
Oligonucleotide primer

&lt;400&gt; 8

acggtgagtg agtagaaaat agttgggaac tggga

35

&lt;210&gt; 9

&lt;211&gt; 43

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:  
Oligonucleotide primer

&lt;400&gt; 9

cgtatgagtg agtagaataa agtcttaaac tgaacaaaat aga

43

&lt;210&gt; 10

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:  
Oligonucleotide primer

&lt;400&gt; 10

aagtagcttt tctgtgactg gt

22

&lt;210&gt; 11

&lt;211&gt; 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
Oligonucleotide primer

<400> 11

gatggcatga cagtaagagc t

21

<210> 12

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
Oligonucleotide primer

<400> 12

agctggcgaa aggggggatgt g

21

<210> 13

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
Oligonucleotide primer

<400> 13

ttatgcttcc ggctcgatatg ttgtgt

26

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 03/00285

## A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C12N 15/11, C12N 15/63, C12N 15/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, BIOSIS, MEDLINE, WPI DATA

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Nucleic Acids Research, Volume 26, No. 8, 1998, Dona York et al, "Simple and efficient generation in vitro of nested deletions and inversions: Tn5intramolecular transposition", pages 1927-1933, see especially page 1930, right column, paragraph 3, page 1932, right column, paragraph 2	1-2,4,7-13
Y	--	3,5-6

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

25 July 2003

Date of mailing of the international search report

28 -07- 2003

Name and mailing address of the ISA/  
Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. +46 8 666 02 86

Authorized officer

SARA NILSSON/BS  
Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 03/00285

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Nucleic Acids Research, Volume 27, No. 13, 1999, Saija Haapa et al, "An efficient and accurate integration of mini-Mu transposons in vitro: a general methodology for functional genetic analysis and molecular biology applications", pages 2777-2784, page 2781, left column, paragraph 2, lines 1-3, last paragraph, page 2782, right column - page 2783  --	3,5-6
X	US 5948622 A (REZNIKOFF ET AL), 7 Sept 1999 (07.09.99), column 3, line 26 - line 31; column 13, line 44 - line 60; column 23, line 46 - column 24, line 5	1-2,4,7-13
Y	--	3,5-6
A	J. Mol. Biol. Volume 314, 2001, Insuk Lee et al, Mu Termini, "Importance of the Conserved CA Dinucleotide at Mu Termini", pages 433-444, see abstract, page 442, left column, paragraph 2  --	1-13
A	Journal of Virology, Volume 74, No. 6, 2000, Louise Chang Laurent et al, "Functional Characterization of the Human Immunodeficiency Virus Type 1 Genome by Genetic Footprinting", pages 2760-2769  --	1-13
A	Trends in Microbiology, Volume 8, No. 12, December 2000, Finbarr Hayes et al, "Pentapeptide scanning mutagenesis: encouraging old proteins to execute unusual tricks"  -- -----	1-13

# INTERNATIONAL SEARCH REPORT

Information on patent family members

29/06/03

International application No.

PCT/FI 03/00285

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5948622 A	07/09/99	AT 238422 T	15/05/03
		AU 732130 B	12/04/01
		AU 4262097 A	26/03/98
		CN 1251135 A	19/04/00
		DE 69721282 D	00/00/00
		EP 0927258 A,B	07/07/99
		SE 0927258 T3	
		JP 2001507565 T	12/06/01
		PL 332145 A	30/08/99
		US 5925545 A	20/07/99
		US 6437109 B	20/08/02
		WO 9810077 A	12/03/98
		US 5965443 A	12/10/99

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**